BridgeBio Pharma, Inc. (BBIO)

NASDAQ: BBIO · USD

$70.8

+1.41 (+2.0%)· Recorded snapshot

Market cap	13.8B
Revenue (ttm)	713.1M
Net income (ttm)	-691.9M
EPS (ttm)	-$3.57
Shares out	195.5M
Volume	2,710,620
Beta	0.97

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 713.1M
Net income (ttm): -691.9M
EPS (ttm): -$3.57
Market cap: 13.8B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Aanhouden

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROEn/a

P25 n/aP50 n/aP75 n/a

ROIC-63.1

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All BBIO indicators

Market & fundamental data

Available fields

206

Groups with data

Currency

USD

Showing 206 of 206 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001743881
Company name	BridgeBio Pharma, Inc.
Country	United States
Country code	US
CUSIP number	10806X102
Earnings date	2026-10-29
Earnings time	amc
Employees	1,003
Employees change	164
Employees growth	19.55%
Enterprise value	$16.5B
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2015
Industry	Biotechnology
IPO date	2019-06-27
Is primary listing	Yes
Is SPAC	No
ISIN number	US10806X1028
Last 10-K release date	2026-02-24
Last earnings date	2026-08-10
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$13.8B
Market cap category	Large-Cap
Next earnings date	2026-10-29
Options	Yes
Price	$70.78
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	BBIO
U.S. state	California
Website	https://bridgebio.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-5.04%
EV/Sales	22.79x
FCF / EV yield	-2.68%
FCF yield	-3.2%
Forward EV/Sales	12.46x
Forward P/S	10.43x
P/S ratio	19.07x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	-67.01%
EBITDA margin	-66.3%
Gross margin	94.44%
Operating margin	-67.01%
Pretax margin	-98.68%
Profit margin	-97.03%
Profit per employee	$-689,796
Revenue per employee	$710,936
ROA	-26%
ROA (5Y)	-44.94%
ROCE	-146.28%
ROIC	-63.06%
SBC / revenue	20.65%
Tax / revenue	-0.23%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	3
EPS growth years	0
Gross profit growth	196.87%
Gross profit growth (Q)	113.85%
Gross profit growth 3Y	505.13%
Gross profit growth 5Y	60.81%
Net income growth quarters	3
Net income growth years	0
Revenue growth	202.39%
Revenue growth (Q)	120.39%
Revenue growth (QoQ)	25.27%
Revenue growth 3Y	400.87%
Revenue growth 5Y	62.6%
Revenue growth quarters	5
Revenue growth years	2

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-1M
Depreciation and amortization	$5.1M
EBIT	$-477.8M
EBITDA	$-472.8M
EPS	$-3.57
FCF per share	$-2.23
Financing cash flow	$398M
Free cash flow	$-435.4M
Free cash flow minus SBC	$-582.6M
Gross profit	$673.4M
Income taxes	$-1.7M
Investing cash flow	$-34.7M
Net borrowing	$601.4M
Net cash flow	$-71.1M
Net income	$-691.9M
Operating cash flow minus SBC	$-581.6M
Operating income	$-477.8M
Revenue	$713.1M
Stock-based compensation	$147.2M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	-3.27
Book value per share	$-12.88
Interest coverage	-2.32
Long-term assets	$124.2M
Long-term liabilities	$2.8B
Net cash (debt)	$-2.7B
Net cash / market cap	-19.51%
Piotroski F-Score	2
Property, plant and equipment	$22.3M
Shareholders' equity	$-2.5B
Tangible book value	$-2.5B
Tangible book value per share	$-13.02
Total assets	$1.2B
Total cash	$720.2M
Total debt	$3.4B
Total liabilities	$3.7B
WACC	8.65%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.62
Current assets	$1.1B
Current liabilities	$890.6M
Current ratio	1.23
Inventory turnover	1.12
Net working capital	$33.6M
Quick ratio	1.09
Working capital	$202.5M
Working capital turnover	1.52

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-2.29%
Dividend yield	0%
Shareholder yield	-2.29%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$73.02
1D price change	2.03%
1M price change	7.84%
1M total return	7.84%
1W price change	4.68%
1W total return	4.68%
1Y price change	11.25%
1Y return CAGR	11.26%
1Y total return	11.25%
20-day SMA	$66.99
200-day SMA	$72.80
3M price change	-15.94%
3M total return	-15.94%
3Y price change	189.32%
3Y return CAGR	42.48%
3Y total return	189.32%
50-day SMA	$70.70
50-day SMA vs 200-day SMA	50under200
52-week high	$93.42
52-week high date	2026-07-09
52-week low	$60.22
52-week low date	2025-11-04
5Y price change	44.51%
5Y return CAGR	7.64%
5Y total return	44.51%
6M price change	-5.11%
6M total return	-5.11%
All-time high	$93.42
All-time high date	2026-07-09
All-time low	$4.98
All-time low date	2022-05-12
Average true range (ATR)	$2.11
Average volume	2.5M
Beta (1Y)	0.18
Beta (2Y)	0.94
Beta (5Y)	0.97
Change from 52-week high	-24.23%
Change from 52-week low	17.54%
Change from all-time high	-24.31%
Change from all-time low	1,319.88%
Change from open	2.43%
Day's gap	-0.39%
Dollar volume	$191.9M
High price	$71.16
Low price	$68.82
Monthly RSI	59.61
Open price	$69.10
Position in 52-week range	83.76%
Premarket change	-0.58%
Premarket close	$69.37
Premarket price	$68.97
Premarket volume	21.1K
Previous close	$69.37
Price vs 150-day SMA	-3.16%
Price vs 20-day SMA	5.55%
Price vs 200-day SMA	-2.87%
Price vs 50-day SMA	0.02%
Relative volume	1.07
Return from IPO open	127.21%
Return from IPO price	309.12%
RSI	59.59
Sharpe ratio	0.37
Sharpe ratio (3Y)	0.87
Sharpe ratio (5Y)	0.52
Sortino ratio	0.69
Sortino ratio (3Y)	1.49
Sortino ratio (5Y)	0.9
Volume	2.7M
Weekly RSI	49.26
YTD price change	-7.56%
YTD total return	-7.56%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	167.2M
Float percentage	85.53%
Shares change (QoQ)	0.51%
Shares change (YoY)	2.29%
Shares held by insiders	3.93%
Shares held by institutions	87.78%
Shares outstanding	195.5M
Short % of float	11.77%
Short % of shares	10.06%
Short ratio	7.2 days

Deeper analysis on BBIO

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this BBIO report

Is a complete BBIO research report available?

No complete published report is available for BridgeBio Pharma, Inc. (BBIO) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

BridgeBio Pharma, Inc. (BBIO)

Price

Financial snapshot

Fair-value bridge

Latest news · BBIO

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All BBIO indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on BBIO

Frequently asked questions